Found 0 matching trials
Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
N/AMultiple sclerosis (MS) is a severe autoimmune disease that affects mainly ...
Location
IMPULS Endowment Fund
Treatments Being Tested
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
N/AThe primary objective of the study is to evaluate the real-world clinical e...
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
PHASE3A study to evaluate the efficacy and safety of fenebrutinib on disability p...
Status
Active Not Recruiting
Location
North Central Neurology Associates
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
PHASE3The study is to evaluate the efficacy and safety of evobrutinib administere...
Location
Research Site 752
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
PHASE3Primary objective was to assess the effectiveness evaluated by the time to ...
Location
Investigational Site Number 056003
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
PHASE3This study determines the Annualized Relapse Rate (ARR) in participants wit...
Location
TG Therapeutics RMS Investigational Trial Site
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
N/ADemyelinating Diseases of the Central Nervous System Registry for Patients ...
Location
Multiple Locations
Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis
N/AThe main goal of multiple sclerosis (MS) treatment is to prevent further re...
Location
University of Ostrava
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
PHASE3The primary objective of this study was to document the long-term safety an...
Location
Investigational Site Number 1032
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
N/AThis non-interventional study aims to observe the effect of early versus la...
Status
Active Not Recruiting
Location
Multiple Locations